Jennifer Metscher
Family · Parsons, KSNPI 1477953479
Payments from drug & device makers
Across 91 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$201
- Lundbeck LLC$118
- Amgen$117
- Abbott$116
- GSK$115
- Axsome Therapeutics, Inc.$100
- plus $754 from 23 others
What the payments were for
- Food & beverage$1,520100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $201 |
| Lundbeck LLC | 6 | $118 |
| Amgen | 7 | $117 |
| Abbott | 7 | $116 |
| GSK | 8 | $115 |
| Axsome Therapeutics, Inc. | 6 | $100 |
| Lilly USA, LLC | 5 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $67 |
| Novo Nordisk | 4 | $67 |
| Boehringer Ingelheim | 4 | $59 |
| Corcept Therapeutics | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Bayer | 1 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Medtronic | 2 | $29 |
| Dexcom, Inc. | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Insulet Corporation | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Ardelyx, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Novartis | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$1,520 in reported general payments places this provider in the 80th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 137 | $154,903 |
| OzempicSemaglutide | 76 | $81,523 |
| JardianceEmpagliflozin | 112 | $81,153 |
| TrulicityDulaglutide | 57 | $65,801 |
| TradjentaLinagliptin | 84 | $49,013 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $47,975 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 39 | $44,000 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $41,146 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $26,434 |
| JanuviaSitagliptin Phosphate | 28 | $21,042 |
| FarxigaDapagliflozin Propanediol | 23 | $20,435 |
| Novolog FlexpenInsulin Aspart | 63 | $19,738 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $17,179 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $15,995 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 22 | $10,642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $84 | $224,526208 claims |
| Boehringer IngelheimJardiance, Tradjenta | $59 | $130,166196 claims |
| Novo NordiskOzempic, Novolog | $67 | $85,86695 claims |
| MerckJanuvia, Janumet Xr | $15 | $27,24139 claims |
| AstraZenecaFarxiga | $14 | $20,43523 claims |
| AbbVieSynthroid | $201 | $1,39321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,579 family providers in Kansas.
Other family in Parsons
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
- Jaimie HeldstabWestwood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.